Levetiracetam for Treatment of Pain Associated With Fibromyalgia

Exclusion Criteria

• •1. Subjects who have demonstrated a hypersensitivity to levetiracetam or who have been previously treated with it.
• •2. Subjects with severe liver or kidney insufficiency (AST, ALT, BUN, Creatinine more than twice the upper limit of the reference range).
• •3. Abnormal Westergen erythrocyte sedimentation rate (e.g. ESR \>40 mm/min)
• •4. Abnormal antinuclear antibody (ANA≥1:160), or rheumatoid factor (RF\>80 IU/ml)
• •5. Subjects with significant hematological disease, such as clotting disorders.
• •6. Subjects who have undergone trigger point injections or other needle-based therapies in the two weeks prior to dosing.
• •7. Subjects having other severe pain that may confound assessment of the pain due to the fibromyalgia.
• •8. Subjects taking or having taken any other experimental drugs, drugs not approved in the United States, or participating in or having participated in other clinical studies in the 2 months prior to this clinical trial.
• •9. Subjects who have a history of illicit drug or alcohol abuse within the last year.
• •10. Pregnant or lactating women.
• •11. Subjects who are considered unreliable as to medication compliance or adherence to scheduled appointments as determined by the investigators
• •12. Subjects who have serious or unstable medical or psychological conditions that in the opinion of the investigator(s), would compromise the subject's participation in the study.
• •13. Subjects involved in any unsettled litigation such as automobile accident, civil lawsuit, or worker's compensation pertaining to their fibromyalgia, current involvement in out-of-court settlements for litigation pertinent to their fibromyalgia, or are currently receiving monetary compensation as a result of any of the above.